Altogether, GIPR agonists have become an attractive pharmacotherapy agent for treating type 2 diabetes mellitus (T2DM) and potentially inducing weight loss in obese patients, like glucagon-like peptide-1 receptor (GLP-1R) agonists (Finan et al. 2016, Samms et al. 2020). Here, GLP1R is linked to type 2 diabetes mellitus.